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Abstract
Background: Boiogito (Japanese herbal medicine, Tsumura Co. Tokyo, Japan) contains sinomenin which inhibits
inflammatory reactions. Since sinomenine is a principle component of the Boiogito, there is a possibility of it being
effective on osteoarthritis (OA) of the knee with joint effusion. However, there is no report concerning the effectiveness
of Boiogito on knee OA. The objective of the present study is to investigate the therapeutic effect of Boiogito on OA of
the knee associated with joint effusion in a comparative study among randomly assigned groups.
Methods: Study was performed using 50 patients who were diagnosed with primary osteoarthritis of the knee
with joint effusion. The patients were randomly assigned to two groups: one group (25 patients) using both
loxoprofen (2-{4-[(2-oxocyclopentyl) methyl]} propanoic acid) and Boiogito and the other group (25 patients) using
loxoprofen, and were evaluated during a 12 week observation period. The assessment parameters including knee
scores in the Knee Society Rating System including Knee score and Functional scores, amount of joint effusion by
joint puncture in clinically detected cases, the 36-items short form of the Medical Outcome Study Questionnaire
(SF-36) as a measurement of health related quality of life were used.
Results: The knee scores based on the Knee Society Rating System were improved in both groups. The staircase
climbing up and down ability in the Knee society rating system functional score was significantly improved in the
group using Boiogito and loxoprofen compared to the loxoprofen group. In the evaluation using SF-36, significant
improvements were found in the scores in both groups in physical functioning after 12 weeks. The amount of
joint fluid was significantly decreased at 4, 8 and 12 weeks compared to pre-administration baseline in the group
using Boiogito and loxoprofen. A side effect of Boiogito, dry mouth, was found in one case. The symptom was
mild and improved immediately after discontinuation of administration.
Conclusion: The results indicated that Boiogito have a possibility for a treatment modality for joint effusion with
osteoarthritis of the knee.
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Introduction
Osteoarthritis (OA) of the knee is a degenerative disease
of the knee joints which significantly damages the func-
tions of knee joints. The objective of its treatment is to
decrease pain while attempting to maintain or increase
the range of knee motion and to minimize disabilities in
daily living. The majority of osteoarthritic patients visit
the clinic with the complaint of pain. As clinical symp-
toms, joint effusion is frequently associated with pain
and limitation in the range of knee motion.
As conservative therapies for OA of the knee, educa-
tion and physical therapy, oral administration of non-
steroidal anti-inflammatory drugs (NSAIDs), intra-
articular injection of hyaluronic acid, and use of lateral
wedge insole or unloading braces are applied based on
the degrees of symptoms [1]. Further, diacerein, which
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as a symptom modifying drug for reducing joint pain in
Europe and the United States of America [2]. It has
been reported that diacerein has the chondromodulating
effect on the hip joint in observating radiographs among
OA patients of the hip joint in a total of 507 cases [3].
Further, diacerein was reported to be effective on OA of
the knee [4]. In Asia, the alkaloid, sinomenine is
extracted from the Chinese medical plant Sinomeniuim
acutum, which has been utilized by Chinese doctors for
over 2000 years to treat various rheumatic diseases [5].
Previous pharmacological studies have demonstrated
that sinomenine inhibits inflammatory reactions [5,6].
Boiogito (Japanese herbal medicine, Tsumura Co.,
Tokyo, Japan) contains a dry extract 3.75 g of the mixed
drug substance consisting of Sinomenium Stem 5.0 g,
Astragalus Root 5.0 g, Atractylodes Lancea Rhizome 3.0
g, Jujube 3.0 g, Glycyrrhiza 1.5 g, and Ginger 1.0 g in a
d a i l yd o s eo f7 . 5g .T h a ti sc o n s t i t u t e do fn u m e r o u s
components including sinomenine as a principal compo-
nent (Figure 1). Since sinomenine is a principle compo-
nent, there is a possibility of it being effective on OA of
the knee with joint effusion. The objective of the present
study is to investigate the therapeutic effect of Boiogito
on OA of the knee associated with joint effusion in a
comparative study among randomly assigned groups.
Materials and methods
The subjects used were patients with primary OA of the
knee associated with clinically detected joint effusion.
T h o s ew e r eo u t p a t i e n t sh a v i n gp a i ni nt h ek n e ej o i n t s
while walking and showing a Kellgren-Lawrence [7]
grade III or less in the radiographs. The patients having
serious complications (liver diseases, kidney diseases,
hematological diseases, etc.), those incapable of taking
oral administration, those currently taking other herbal
Figure 1 Three Dimensional pattern of High Performance Liquid Chromatography in Boiogito. HPLC apparatus consisted of a Shimadzu
LC 10A (analysis system software: CLASS-M10A ver. 1.64, Tokyo, Japan) equipped with a multiple wavelength detector (UV 200-400 nm)
(Shimadzu SPD-M10AVP, diode array detector), an auto injector (Shimadzu CTO-10AC). HPLC conditions were described as follows: column, ODS
(TSK-GEL 80TS, 250 × 4.6 mm i.d., TOSOH, Tokyo, Japan); eluent, (A) 0.05 M AcONH4 (pH 3.6) (B) 100% CH3CN. A linear gradient of 90% A and
10% B changing over 60 min to 0% A and 100% B was used. And 100% B was continued for 20 min.; temperature, 40 degrees celusius; flow
rate, 1.0 mL/min. A granule was extracted with methanol (20 mL) under ultrasonication for 30 min., and was centrifuged at 3000 rpm for 5 min.
The supernatant was filtrated with a membrane filter (0.45 μm) and then submitted for HPLC analysis (30 μL).
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to the joint were excluded from the study. After
approval of the Institutional Review Board at the Hok-
kaido University Hospital, a random, blinded inter-
group comparison study was conducted.
T h es u b j e c t sw e r er a n d o m l yd i v i d e di n t ot w og r o u p s :
one group treated by concomitant use of Boiogito and
loxoprofen (thereinafter referred to as the concomitant
use group) and loxoprofen administration group (here-
inafter referred to as the loxoprofen group). Prior to the
study, the subjects signed a written consent of their own
free will. The treatment drug, Boiogito, was adminis-
tered at a daily dose of 7.5 g divided into three portions
which were given before meals or between meals.
Further, loxoprofen at a single dose of 60 mg was orally
administered after meals three times daily. The number
of subjects enrolled in the present study was 50 subjects
divided into 25 subjects in the concomitant use group
and 25 subjects in the loxoprofen group with respect to
the treatment drugs. Among them, three cases including
two cases (loxoprofen group) who did not come back
after the initial examination and one case (concomitant
use group) who did not come back after 4
th week were
excluded from the study. As a result, the remaining 47
subjects (24 cases in the concomitant use group and 23
cases in the loxoprofen group) were used in the analysis
of the treatment results.
The period of administration of the treatment drug
was 12 weeks. The assessment parameters including
knee scores in the Knee Society Rating System including
Knee score and Functional scores [8], amount of joint
effusion by joint puncture in clinically detected cases,
the 36-items short form of the Medical Outcome Study
Questionnaire (SF-36) as a measurement of health
related quality of life were used. Further, the side effects
were investigated.
For statistical analyses, according to the types of data,
the following methods were used: c
2 tests for ratio of
male and female, Wilcoxon’s T- test for patients back-
ground, change in SF-36 and Knee Society Rating Sys-
tem knee score and functional scores, one-way analysis
of variance for change in volume of joint fluid, and
then, a Bonferroni analysis was applied to determine the
significance of difference for multiple comparison. Sig-
nificant level was set at p < 0.05.
Results
Regarding the patients’ background, with respect to gen-
der in both groups, the number of females was greater
than the number of males. The mean age was 68.3 years
in the concomitant use group and 71.5 years in the lox-
oprofen group. The detailed preoperative comparison
between the 2 groups is shown in Table 1. There were
no significant differences in preoperative factors
between the two groups.
The knee score in the Knee Society Rating System was
75.0 +/- 15.1 before administration in the concomitant
use group which improved to 85.8 +/- 11.1 at the time
of final observation and 72.8 +/- 16.0 before administra-
tion in the loxoprofen group which improved to 81.7
+/- 15.1, demonstrating significant improvements in
both groups (p < 0.05). The staircase climbing up and
down ability in the Knee Society Rating System of func-
tional score significantly improved from 32.2 +/- 6.3
before administration to 40.2 +/- 4.4 at the time of final
observation in the concomitant use group (p < 0.05). In
the loxoprofen group, the functional score of stairs in
Knee Society Rating System changed from 28.4 +/- 6.4
before administration to 36.6 +/- 6.2 at the final follow
up. This change has no significant difference.
In the evaluation of SF-36 which is an assessment of
the quality of life of the patients, significant
Table 1 Patient demographics
Concomitant use group (Loxoprofen and
Boiogito)
Loxoprofen group
(Loxoprofen)
p-
value
Number of patients 24 23 -
Sex Female 19 18 -
Male 5 5 -
Average age 68.3 +/- 10.0 71.5 +/- 6.0 N.S
Height (cm) 154.0 +/- 6.9 152.5 +/- 6.2 N.S
Weight (kg) 61.7 +/- 6.2 62.3 +/- 5.7 N.S
Average period of symptoms 14.5 +/- 30 25.0 +/- 23.1 N.S
Knee score in Knee Society Rating System 75.0 +/- 15.1 72.8 +/- 16.0 N.S
Functional score in Knee Society Rating
System
32.2 +/- 6.3 28.4 +/- 6.4 N.S
Number of Kellgren-Lawrence Grade II: 2 II: 2 -
III:22 III:21
Data is shown as mean and standard deviation.
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sical functions after 12 weeks (p < 0.05) (Boiogito and
loxoprofen administration group in Figure 2, Loxoprofen
administration group in Figure 3).
In terms of quantity of joint effusion, the quantity of
joint effusion was an average of 15.1 +/- 7.1 ml in the
concomitant use group and an average of 12.1 +/- 5.7
ml in the loxoprofen group when punctured before the
treatment. There was no significant difference in quan-
tity of joint effusion between two groups before admin-
istration. The amounts of joint effusion at the times of 4
weeks, 8 weeks and 12 weeks after treatment were sig-
nificantly lower compared to those prior to the treat-
ment in the concomitant use group (p < 0.05). On the
other hand, there were no significant differences in the
amount of joint effusion at the time of 4, 8, and 12
weeks after treatment compared to those before treat-
ment in the loxoprofen group (Figure 4).
As a side effect which seemed to be caused by admin-
istration of Boiogito, one case of “dry mouth” was
reported. The symptom was mild and was improved
immediately after discontinuation of administration.
Discussion
OA of the knee is a degenerative disease which onsets
mostly among the elderly. The number of osteoarthritic
patients is simply increasing in society due to the
increasing number of the elderly population. The clinical
symptoms of OA of the knee include pain as well as
limitation in the range of knee motion and joint effu-
sion. As the OA of the knee advances, the symptoms
cause a significant effect on activities of daily living.
When the degeneration of knee joints is not severe,
conservatinve treatment including drug therapies and
physical therapies are selected. For pain management,
NSAIDs are widely used. It has been reported that
NSAIDs have a major role in the management of OA in
a systematic review [9,10]. On the other hand, problems
such as an inhibitory action of long-term application of
NSAIDs on proteoglycan synthesis of cartilage was
pointed out [11,12]. In some cases, joint effusion exists
in spite of various treatments. The joint effusion in the
knee contains many aggrecan fragments and MMP-1. It
has been reported that joint effusion has adverse effects
on the articular cartilage [13,14]. According to the
results of the present study, joint effusion in OA of the
knee significantly decreased by using Boiogito along
with NSAIDs. In addition, staircase climbing up and
down ability in the knee society score and Physical func-
tioning of SF-36 were found to be improved signifi-
cantly. These phenomena were assumed to be related to
the fact that systematic conditions were improved as a
result of improvement in joint effusion by Boiogito.
Figure 2 Change of SF-36 in Boiogito and loxoprofen
administration group. PF: Physical functioning, RP: Role physical,
BP: Bodily pain, GH: General health perceptions, VT: Vitality, SF: Social
functioning, RE: Role emotion, MH: Mental health. Data is shown as
mean and standard deviation.
Figure 3 Change of SF-36 in Loxoprofen administration group.
PF: Physical functioning, RP: Role physical, BP: Bodily pain, GH:
General health perceptions, VT: Vitality, SF: Social functioning, RE:
Role emotion, MH: Mental health. Data is shown as mean and
standard deviation.
Figure 4 Change in volume of joint fluid. Data is shown in mean
and standard deviation.
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tive in the conservative treatment for OA of the knee.
Boiogito and loxoprofen treatment improve pain and
joint effusion, however, their SF-36 scores about another
physical area (role physical, bodily pain and general
health) were not improve significantly. On the other
hand, specific evaluation for knee function according to
Knee Society Rating System showed significant differ-
ence. These results may be attributed that SF-36 is com-
prehensive scale and not disease specific scale.
Since herbal medicines consist of numerous compo-
nents instead of a single component, the mechanisms of
decreasing the amount of joint effusion are still
unknown. However, with respect to the pharmacological
action of Boiogito, effectiveness of sinomenine for
inflammation which is a component included in the
drug substance was reported in the adjuvant arthritis
model [15]. It was assumed that sinomenine inhibits
inflammation of secondary synovitis in OA of the knee.
It have been reported that other herbal medicine con-
taining astragalus have anti-inflammatory activity
through decreasing inflammation related cytokine,
Tumor Necrosis Factor (TNF) alpha and Interferon
gamma in a rat autoimmune myocarditis model, mice
dermatitis model and diabetic mice [16-18]. These
reports were not studied on osteoarthritis, however,
astragalus which is contained in Boiogito have also pos-
sibility for decreasing symptoms of osteoarthritis with
joint effusion.
Concerning the limitation of the present study, we did
not investigate the single administration of Boiogito and
also there is a limitation that the number of cases is
small. The studies using a larger number of subjects and
the studies including analysis of pharmacological actions
based on the analysis of the characteristic changes in
the joint effusion should be needed. Further, it is neces-
sary to have a long-term assessment including the
degree of satisfaction by patients in the general evalua-
tion not only from the local results in the knees.
In conclusion, this is the first report that the herbal
remedy “Boiogito” h a v eap o s s i b i l i t yo fc o n s e r v a t i v e
treatment for joint effusion associated with OA of the
knee.
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